103 related articles for article (PubMed ID: 29896287)
1. Higher Plasma Fibrinogen Levels are Associated with Malignant Phenotype and Worse Survival in Patients with Glioblastomas.
Wang PF; Meng Z; Song HW; Yao K; Duan ZJ; Li SW; Yan CX
J Cancer; 2018; 9(11):2024-2029. PubMed ID: 29896287
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Value of ATRX and p53 Status in High-Grade Glioma Patients in Morocco.
Squalli Houssaini A; Lamrabet S; Senhaji N; Sekal M; Nshizirungu JP; Mahfoudi H; Elfakir S; Karkouri M; Bennis S
Cureus; 2024 Mar; 16(3):e56361. PubMed ID: 38633919
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylated Hsp27 is mutually exclusive with ATRX loss and the IDH1
Cai HQ; Wang PF; Zhang HP; Cheng ZJ; Li SW; He J; Zhang Y; Hao JJ; Wang MR; Yan CX; Wan JH
J Clin Pathol; 2018 Aug; 71(8):702-707. PubMed ID: 29550762
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
Chaurasia A; Park SH; Seo JW; Park CK
J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
[TBL] [Abstract][Full Text] [Related]
5. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
6. Preoperative inflammation markers and IDH mutation status predict glioblastoma patient survival.
Wang PF; Song HW; Cai HQ; Kong LW; Yao K; Jiang T; Li SW; Yan CX
Oncotarget; 2017 Jul; 8(30):50117-50123. PubMed ID: 28223536
[TBL] [Abstract][Full Text] [Related]
7. Radiogenomics correlation between MR imaging features and major genetic profiles in glioblastoma.
Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
Eur Radiol; 2018 Oct; 28(10):4350-4361. PubMed ID: 29721688
[TBL] [Abstract][Full Text] [Related]
8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
9. Loss of BCAT1 Expression is a Sensitive Marker for IDH-Mutant Diffuse Glioma.
Chen YY; Ho HL; Lin SC; Hsu CY; Ho DM
Neurosurgery; 2019 Sep; 85(3):335-342. PubMed ID: 30113684
[TBL] [Abstract][Full Text] [Related]
10. ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis.
Wiestler B; Capper D; Holland-Letz T; Korshunov A; von Deimling A; Pfister SM; Platten M; Weller M; Wick W
Acta Neuropathol; 2013 Sep; 126(3):443-51. PubMed ID: 23904111
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Rajmohan KS; Sugur HS; Shwetha SD; Ramesh A; Thennarasu K; Pandey P; Arivazhagan A; Santosh V
J Clin Pathol; 2016 Aug; 69(8):686-94. PubMed ID: 26743027
[TBL] [Abstract][Full Text] [Related]
12. ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors.
Cai J; Zhang C; Zhang W; Wang G; Yao K; Wang Z; Li G; Qian Z; Li Y; Jiang T; Jiang C
Oncoscience; 2016; 3(7-8):258-265. PubMed ID: 27713914
[TBL] [Abstract][Full Text] [Related]
13. ATRX status correlates with 11 C-methionine uptake in WHO grade II and III gliomas with IDH1 mutations.
Ogishima T; Tamura K; Kobayashi D; Inaji M; Hayashi S; Tamura R; Nariai T; Ishii K; Maehara T
Brain Tumor Pathol; 2017 Jan; 34(1):20-27. PubMed ID: 28251430
[TBL] [Abstract][Full Text] [Related]
14. Low FoxG1 and high Olig-2 labelling indices define a prognostically favourable subset in isocitrate dehydrogenase (IDH)-mutant gliomas.
Schäfer S; Behling F; Skardelly M; Koch M; Ott I; Paulsen F; Tabatabai G; Schittenhelm J
Neuropathol Appl Neurobiol; 2018 Feb; 44(2):207-223. PubMed ID: 29053887
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of prognostic nutritional index in patients with glioblastomas.
Ding JD; Yao K; Wang PF; Yan CX
Medicine (Baltimore); 2018 Nov; 97(48):e13218. PubMed ID: 30508902
[TBL] [Abstract][Full Text] [Related]
16. IDH1-Mutation in Diffuse Gliomas in Persons Age 55 Years and Over.
Robinson C; Kleinschmidt-DeMasters BK
J Neuropathol Exp Neurol; 2017 Feb; 76(2):151-154. PubMed ID: 28110298
[TBL] [Abstract][Full Text] [Related]
17. TERT promoter wild-type glioblastomas show distinct clinical features and frequent PI3K pathway mutations.
Williams EA; Miller JJ; Tummala SS; Penson T; Iafrate AJ; Juratli TA; Cahill DP
Acta Neuropathol Commun; 2018 Oct; 6(1):106. PubMed ID: 30333046
[TBL] [Abstract][Full Text] [Related]
18. Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.
Fukai J; Arita H; Umehara T; Yoshioka E; Shofuda T; Kanematsu D; Kodama Y; Mano M; Kinoshita M; Okita Y; Nonaka M; Uda T; Tsuyuguchi N; Sakamoto D; Uematsu Y; Nakao N; Mori K; Kanemura Y
Brain Tumor Pathol; 2020 Apr; 37(2):50-59. PubMed ID: 32361941
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
20. Ultra-Mutation in
Barresi V; Simbolo M; Mafficini A; Piredda ML; Caffo M; Cardali SM; Germanò A; Cingarlini S; Ghimenton C; Scarpa A
Cancers (Basel); 2019 Aug; 11(9):. PubMed ID: 31480372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
